Cipla Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/i3pduqc9ely0y96gt7sta0cl.pdf

Key Takeaways


The Chronic Mix Shift & India Franchise

Umang Vohra: "Well, not really, because I think what we've been saying is that the sustainable margins the way we see it in this quarter is in the range of 24 to 25. Because if you look at the type of mix we've seen this quarter is very different, hardly any anti-infective and we know that there is some amount of anti-infective that comes in the winter months."

North America: Record Revenue & Pipeline Progression

Umang Vohra: "I think that fortunately or unfortunately is not completely in our control because the market buying behavior is dependent on which variant they keep. So, in the event that they decide to keep the variant, obviously, the share will go up. In the event they don't, then the share will only increase marginally as it has been doing."

Margin Walk & Cost Structure


South Africa & Emerging Markets


Pipeline & Strategic Bets


Guidance & Commitments

CommitmentSpecificsTimeline
Full-year EBITDA margin23–24% with bias toward higher end; full year to land at about 24%FY24
Generic Symbicort filingFiling from multiple internal facilitiesQ3 FY24
Peptide launch (first product)One product launch; impact depends on timing within quarterQ4 FY24
Peptide launches (follow-on)Three to four launches plannedFY25
Goa reinspection submissionCAPA complete; requisite data to be submitted to enable reinspectionSoon (undated)
India long-term growthApproximately 12% on a five-year multi-year basis5-year horizon
QCIL reportingDiscontinued from next quarterQ3 FY24 onward
US quarterly revenue run rateSustainable range of $220–225 million for next quarterQ3 FY24

Key Metrics

MetricQ2 FY24
Revenue₹6,678 cr, highest ever quarterly revenue, +15% YoY
Revenue (ex-QCIL)₹6,490 cr, +14% YoY
EBITDA₹1,690 cr, 26% of revenue
EBITDA margin26%, record level; full-year guidance raised to 23–24% with bias towards higher end
Profit after tax₹1,131 cr, 17% of sales
Gross margin (after materials cost)65.4%, +240 bps YoY
R&D spend₹379 cr, 5.7% of revenue, +13% YoY
Total expenses (employee + other)₹2,631 cr, +1% QoQ; employee and other expenses combined +11–11.5% YoY
Effective tax rate27.5%, constant sequentially
Net cash balance₹6,811 cr (cash equivalents), post dividend payment; debt of ZAR72 cr in South Africa
North America revenue$229 million, +28% YoY, highest ever
North America revenue guidance$220–$225 million sustainable quarterly run rate for Q3 FY24
India business growth~11% internal growth for branded prescription and trade generics; overall One India franchise +10%
Chronic therapy share (India portfolio)60%, +140 bps YoY
South Africa private market secondary growth10% vs market growth of 4%
Lanreotide market share20% as per IQVIA August 2023
Albuterol market share12.9%, +90 bps vs Q1 FY24
BRONCOL market share (South Africa OTC)~50% as per IQVIA MAT August 2023
Impairment charge₹53 cr, partial impairment of non-operational domestic unit and US acquired product intangible
Return on invested capital (LTM)~27%